Programmable Biologics: The Next Therapeutic Frontier
Dr. Marcus Adeyemi
LeMay Publishing
HEALTHCARE
Programmable Biologics: The Next Therapeutic Frontier
Biotech12,899 words74 chapters
Published by LeMay Publishing. 12,899 words across 74 chapters.
About This Publication
A comprehensive examination of programmable biological therapeutics, tracing the evolution from empirical pharmacopeias to engineered living medicines that can sense, compute, and respond to disease states in real time.
Published by LeMay Publishing, a division of LeMay. Massachusetts.
ISBN: 979-8-0000-7001-7
Chapters
1PROGRAMMABLE BIOLOGICS: THE NEXT THERAPEUTIC FRONTIER
2ABOUT THE AUTHOR
3TABLE OF CONTENTS
4PREFACE
5CHAPTER 1
6THE BIOLOGICAL PROGRAMMING PARADIGM
71.1 From Pharmacology to Programming
81.2 Defining Programmability in Biological Therapeutics
91.3 The Convergence of Enabling Disciplines
101.4 A Taxonomy of Programmable Biologics
111.5 The Programmable Biologics Value Chain
121.6 Scope and Significance
13CHAPTER 2
14mRNA THERAPEUTICS — PLATFORM ARCHITECTURE AND CLINICAL REACH
152.1 Foundations of the mRNA Platform
162.2 Molecular Architecture of Therapeutic mRNA
172.3 Nucleoside Modification and Innate Immune Evasion
182.4 Lipid Nanoparticle Delivery
192.5 Clinical Applications: Beyond Vaccines
202.6 Challenges and Limitations
21CHAPTER 3
22ENGINEERED CELL THERAPIES — DESIGN, CONTROL, AND DEPLOYMENT
233.1 The Living Drug Concept
243.2 Chimeric Antigen Receptor (CAR) T Cell Therapy
253.3 Beyond CD19: Expanding the Target Repertoire
263.4 Allogeneic and Universal Cell Therapies
273.5 Engineered Natural Killer Cells and Macrophages
283.6 Safety Engineering: Kill Switches, Logic Gates, and Control Systems
29CHAPTER 4
30GENE CIRCUITS AND SYNTHETIC CONTROL SYSTEMS
314.1 Engineering Biological Computation
324.2 Fundamental Circuit Motifs
334.3 Therapeutic Applications of Synthetic Gene Circuits
344.4 Challenges in Gene Circuit Engineering
35CHAPTER 5
36PROTEIN ENGINEERING AND DESIGNED BIOLOGICS
375.1 The Programmable Protein
385.2 Antibody Engineering
395.3 De Novo Protein Design
405.4 Machine Learning in Protein Therapeutics
41CHAPTER 6
42DELIVERY SYSTEMS — VECTORS, NANOPARTICLES, AND TARGETING STRATEGIES
436.1 The Delivery Imperative
446.2 Viral Vectors
456.3 Non-Viral Delivery Systems
466.4 Targeting Strategies
47CHAPTER 7
48MANUFACTURING, SCALABILITY, AND REGULATORY LANDSCAPES
497.1 The Manufacturing Challenge
507.2 mRNA Manufacturing
517.3 Cell Therapy Manufacturing
527.4 Regulatory Frameworks
53CHAPTER 8
54CLINICAL TRANSLATION — FROM BENCH TO BEDSIDE
558.1 The Translational Gap
568.2 Clinical Trial Design for Programmable Biologics
578.3 Real-World Evidence and Long-Term Follow-Up
58CHAPTER 9
59ETHICAL, SOCIETAL, AND ECONOMIC DIMENSIONS
609.1 The Access Imperative
619.2 Germline Modification and Heritable Changes
629.3 Informed Consent and Patient Autonomy
639.4 Intellectual Property and Innovation Incentives
649.5 Environmental and Biosecurity Considerations
65CHAPTER 10
66THE HORIZON — NEXT-GENERATION PROGRAMMABLE THERAPEUTICS
6710.1 In Vivo Cell Engineering
6810.2 Epigenome Editing
6910.3 RNA Editing and Base Editing
7010.4 Synthetic Microbiome Therapeutics
7110.5 Artificial Intelligence-Driven Therapeutic Design
7210.6 Convergence and the Therapeutic Singularity
73GLOSSARY OF KEY TERMS
74BIBLIOGRAPHY